Xencor doses first patient in phase 1 clinical trial of XmAb14045
"XmAb14045 is a bispecific antibody that engages the immune system against AML," said Paul Foster, M.D., chief medical officer at Xencor. "Built on the scaffold of Xencor's XmAb
SK bioscience is set to lead the Gates Foundation-fundedResearch Optimization & Trial Outcome Recommender (ROTOR) project, an AI-based platform aimed at reducing uncertainty in vaccine-development decisions.
The combination of EPAM’s strong Big Data solutions practice and Sinequa’s unique Cognitive Search and Analytics platform offers customers the ability to gain quick, actionable insights from their
Based in Cambridge of Massachusetts, the new company will develop new comprehensive solutions which will include devices, software, medicine and professional care for diabetes management. The new JV